Recent

% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

  • rivalmoney rivalmoney Nov 19, 2012 8:43 AM Flag

    New Upgrade speaks of the likelihood

    That CLSN's heat trial passes with flying colors and the large worldwide market. Called $18 to conservative

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Is this Griffin again?

    • Also sited:

      The HEAT Study has been designated as a Priority Trial for liver cancer by the National Institutes of Health, has received Fast Track Designation from the FDA and has received Orphan Drug Designation in both the U.S. and Europe. ThermoDox(R) is also being evaluated in two Phase II trials for patients with recurrent chest wall breast cancer and colorectal liver metastases.

      "Celsion stands focused on ThermoDox(R)'s transformative potential for the largest unmet need remaining in oncology. With positive results from the HEAT Study, we are preparing to introduce the first and most important 1st line drug therapy ever for non-resectable HCC. If successful, we will create substantial value for all of our stakeholders, including the global oncology community, our investors and most importantly HCC patients and their families," said Michael H. Tardugno, Celsion's President and Chief Executive Officer. "Preparedness leading up to this event is paramount. We have worked to ensure that the HEAT Study is robust and well conducted. We have maintained constant communication with our study sites, our manufacturers and with regulators to ensure a clean, consistent and high quality data package for review in markets around the world. Further, we enter this period with a strong balance sheet, including financial resources that will take us well beyond data and into multiple indications where the promise of ThermoDox(R) will significantly improve treatment outcomes."

      Mr. Tardugno added, "The momentum behind ThermoDox(R) and our technology platform is evident in the growing interest within industry and the medical and academic communities to explore their application in a broad range of cancers and indications. Following the outcome of the HEAT Study, we intend to accelerate our on-going development programs, an effect that will ultimately reveal the significant potential and elegance of our targeted tumor technology."

 
CLSN
1.49+0.02(+1.36%)May 24 4:00 PMEDT